e-Therapeutics plc Director Dealing and Issue of Equity (2601F)
06 Juillet 2023 - 6:27PM
UK Regulatory
TIDMETX
RNS Number : 2601F
e-Therapeutics plc
06 July 2023
E-THERAPEUTICS PLC
("e-therapeutics" or the "Company")
DIRECTOR DEALING AND ISSUE OF EQUITY
London, UK, 6 July 2023 - e-therapeutics plc (AIM: ETX), the
drug discovery company, announces that o n 6 July 2023, Professor
Trevor Jones (Non-Executive Chairman of the Company) subscribed for
a total of 34,830 new ordinary shares of 0.1p each in the Company
(the "New Ordinary Shares") a t a price of 21.71 pence per share.
The subscription monies paid for the New Ordinary Shares represent
50% of Professor Jones' Non-Executive Director fees net of tax paid
during the period from 31 December 2022 to 30 June 2023 in
accordance with the agreement entered into with Professor Jones,
previously announced o n 5 October 2016, by which Professor Jones
agreed, with effect from 1 October 2016, to invest 50% of his
annual Non-Executive Director fees net of tax in new
e-therapeutics' ordinary shares. Such new shares are issued to
Professor Jones on the first business day after 31 December and 30
June in each year. The subscription price to be paid is the average
of the closing mid-market price for the five business days prior to
the date of issue.
Following Admission, Professor Jones will be interested in a
total of 1,202,571 ordinary shares of 0.1p in the Company,
representing approximately 0.21% of the Company's issued share
capital.
Application has been made to AIM for the admission of the New
Ordinary Shares to trading on AIM ("Admission") and Admission is
expected to occur at 8:00 a.m. on or around 12 July 2023. The New
Ordinary Shares will rank pari passu in all respects with the
Company's existing ordinary shares in issue.
Following Admission, the total number of ordinary shares in the
Company with voting rights in issue will be 582,694,162. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the Financial Conduct Authority's Disclosure and
Transparency Rules.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further details:
Details of the person discharging managerial responsibilities/person
1 closely associated
a) Name Trevor Jones
-------------------------- -------------------------------------------
Reason for the notification
2
-----------------------------------------------------------------------
a) Position/status Non-Executive Chairman
-------------------------- -------------------------------------------
b) Initial notification/ Initial notification
Amendment
-------------------------- -------------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name e-therapeutics plc
-------------------------- -------------------------------------------
b) LEI 21380049RHSSJXWKYT18
-------------------------- -------------------------------------------
Details of the transaction(s): section to be repeated for
4 (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.1 pence
financial instrument,
type of instrument ISIN: GB00B2823H99
Identification code
-------------------------- -------------------------------------------
b) Nature of the transaction Purchase of shares
-------------------------- -------------------------------------------
c) Price(s) and volume(s) 34,830 ordinary shares at a price of 21.71
pence per share
-------------------------- -------------------------------------------
d) Aggregated information 34,830 ordinary shares
- Aggregated volume 21.71 pence per share
- Price Aggregated value: GBP7,561.5 9
-------------------------- -------------------------------------------
e) Date of the transaction 6 July 2023
-------------------------- -------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- -------------------------------------------
For further information, please contact:
e-therapeutics plc
Ali Mortazavi, CEO Tel: +44 (0)1993 883
Laura Roca-Alonso, COO/CBO 125
www.etherapeutics.co.uk
------------------------------------------------ -------------------------
SP Angel Corporate Finance LLP Tel: +44(0)20 3470 0470
Nominated Adviser and Broker
Matthew Johnson/Harry Davies-Ball (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)
------------------------------------------------ -------------------------
About e-therapeutics plc
About e-therapeutics plc
e-therapeutics plc ("ETX") integrates computational power and
biology information to discover life-transforming RNAi medicines.
The Company's technology uses computation to capture and model
human biology, identify novel targets, and develop RNAi medicines
against those targets that can be rapidly progressed to the
clinic.
ETX's proprietary HepNet (TM) platform enables the generation
and analysis of biological network models, providing a novel and
mechanistic approach to drug discovery. This approach explicitly
considers the true complexity of biology to make more reliable
predictions from large complex data sets and ETX's proprietary
hepatocyte knowledgebase - the world's most comprehensive and
integrated hepatocyte-centric data resource. The Company generates,
prioritises and tests millions of hypotheses in silico to identify
better therapeutic targets with higher confidence.
GalOmic (TM) , ETX's proprietary RNAi platform, enables the
targeted delivery to hepatocytes in the liver and the specific
silencing of novel disease-associated genes, identified by HepNet
(TM) . The focus on hepatocytes offers the opportunity to tackle a
wide variety of diseases. The liver is a highly metabolically
active organ which performs a key role in many biological processes
and vital functions crucial for human health. ETX's GalOmic (TM)
constructs have demonstrated compelling in vivo performance in
terms of depth of gene silencing and duration of action.
The Company is progressing a pipeline of first-in-class
preclinical RNAi candidates across several high unmet medical needs
in cardiometabolic indications and targeting promising
hepatocyte-expressed targets with effects in other disease areas.
ETX has also partnered with biopharma companies such as Novo
Nordisk, Galapagos NV and iTeos Therapeutics using its
computational network biology approach across a diverse range of
drug discovery projects.
The Company is based in London, UK and listed on the Alternative
Investment Market of the London Stock Exchange ("AIM"), with ticker
symbol ETX. E-therapeutics is also traded on the OTCQX Best Market
(OTCQX) in the United States, under ticker symbol ETXPF.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFFRDSIRIIV
(END) Dow Jones Newswires
July 06, 2023 12:27 ET (16:27 GMT)
E-therapeutics (LSE:ETX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
E-therapeutics (LSE:ETX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
